Metotreksat Ebewe

Methotrexate, the active ingredient in Metotreksat Ebewe, is an antimetabolite (folate antagonist) presented as an intravenous solution for parenteral use. It is employed in the management of autoimmune disorders and certain malignancies, acting on rapidly dividing cells. GNH USA supplies Metotreksat Ebewe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Methotrexate is used across several disease families, primarily targeting immune‑mediated and proliferative conditions.

Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Psoriasis: decreases skin lesion severity and plaque formation. Acute lymphoblastic leukemia: interferes with leukemic cell replication. Osteosarcoma: used as part of multi‑agent chemotherapy protocols.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting - Fatigue or malaise - Oral mucosal ulceration - Transient elevation of liver enzymes - Mild alopecia - Decreased white blood cell count

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis - Pulmonary toxicity (interstitial pneumonitis) - Bone marrow failure leading to pancytopenia - Acute renal failure - Life‑threatening infection due to immunosuppression - Anaphylactic or severe hypersensitivity reactions

Before initiating therapy, clinicians should assess baseline health status and monitor patients regularly.

Monitor blood counts: perform complete blood count before each dose. Assess liver function: check transaminases and bilirubin regularly. Evaluate renal function: measure serum creatinine and adjust dosing as needed. Avoid in pregnancy: contraindicated due to teratogenic risk. Review concomitant nephrotoxic or hepatotoxic drugs: adjust or discontinue as appropriate. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medications that can alter its safety or efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Trimethoprim‑sulfamethoxazole: potentiates bone marrow suppression. - Live vaccines: risk of severe infection. - Azathioprine or other immunosuppressants: additive myelosuppression. - High‑dose penicillins: may reduce renal clearance.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may increase serum methotrexate levels. - Sulfonamide antibiotics: potential additive hematologic effects. - Antacids containing aluminum or magnesium: may affect absorption of oral forms. - Phenytoin: may alter hepatic metabolism. - Vitamin supplements containing folic acid: may reduce efficacy, requiring dose adjustment.